Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL14989068 | 1.00 | ADRB2 (0.94) | ADRB2CHRM3 | |
| SCHEMBL738893 | 0.97 | ADRB2 (1.00) | ADRB2CHRM3 | |
| SCHEMBL3107050 | 0.97 | ADRB2 (1.00) | ADRB2CHRM3 | |
| Trifluoroacetic Acid SCHEMBL14989003 | 0.95 | ADRB2 (0.94) | ADRB2CHRM3 | |
| Trifluoroacetic Acid SCHEMBL20720566 | 0.95 | ADRB2 (0.94) | ADRB2CHRM3 | |
| Trifluoroacetic Acid SCHEMBL14988931 | 0.95 | ADRB2 (0.94) | ADRB2CHRM3 | |
| SCHEMBL741790 | 0.92 | ADRB2 (1.00) | ADRB2CHRM3 | |
| SCHEMBL3103435 | 0.92 | ADRB2 (1.00) | ADRB2CHRM3 | |
| SCHEMBL3116888 | 0.92 | ADRB2 (1.00) | ADRB2CHRM3 | |
| SCHEMBL739957 | 0.92 | ADRB2 (1.00) | ADRB2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10358433-B2 | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | THERAVANCE RESPIRATORY COMPANY, LLC (US) | 2019-07-23 | — | — | US | disclosed |
| US-20190047984-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | THERAVANCE RESPIRATORY COMPANY, LLC | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190047984-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | ADRB2, ADRB1, ADRA2B | ADRB2 1/4885CHRM3 17/4885 |
| US-10358433-B2 | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | ADRB2, ADRB1, ADRA2A | ADRB2 1/4885CHRM3 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.